Equities research analysts predict that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will report earnings per share of $0.12 for the current quarter, according to Zacks Investment Research. Ten analysts have issued estimates for BioMarin Pharmaceutical’s earnings, with estimates ranging from ($0.02) to $0.21. BioMarin Pharmaceutical posted earnings per share of ($0.07) during the same quarter last year, which would suggest a positive year over year growth rate of 271.4%. The business is scheduled to announce its next quarterly earnings report on Thursday, October 25th.

On average, analysts expect that BioMarin Pharmaceutical will report full year earnings of $0.64 per share for the current financial year, with EPS estimates ranging from $0.57 to $0.76. For the next year, analysts forecast that the business will post earnings of $1.30 per share, with EPS estimates ranging from $0.85 to $1.71. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). BioMarin Pharmaceutical had a negative return on equity of 3.00% and a negative net margin of 8.68%. The business had revenue of $372.80 million during the quarter, compared to analysts’ expectations of $359.25 million. During the same quarter in the prior year, the firm earned ($0.21) EPS. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year.

Several research analysts have recently weighed in on BMRN shares. BidaskClub cut BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 24th. Wedbush boosted their price target on BioMarin Pharmaceutical from $112.00 to $115.00 and gave the stock an “outperform” rating in a research note on Friday, May 25th. Morgan Stanley boosted their price target on BioMarin Pharmaceutical from $113.00 to $115.00 and gave the stock an “overweight” rating in a research note on Friday, August 3rd. Credit Suisse Group boosted their price target on BioMarin Pharmaceutical from $116.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, May 25th. Finally, Zacks Investment Research cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $116.28.

In related news, EVP Jeffrey Robert Ajer sold 1,436 shares of BioMarin Pharmaceutical stock in a transaction on Monday, June 11th. The stock was sold at an average price of $90.31, for a total value of $129,685.16. Following the completion of the sale, the executive vice president now owns 50,135 shares of the company’s stock, valued at $4,527,691.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian Mueller sold 2,021 shares of BioMarin Pharmaceutical stock in a transaction on Friday, June 15th. The stock was sold at an average price of $94.50, for a total value of $190,984.50. Following the completion of the sale, the senior vice president now directly owns 13,029 shares of the company’s stock, valued at approximately $1,231,240.50. The disclosure for this sale can be found here. Insiders sold 65,874 shares of company stock valued at $6,259,566 in the last ninety days. 1.90% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Scout Investments Inc. grew its holdings in shares of BioMarin Pharmaceutical by 125.6% in the second quarter. Scout Investments Inc. now owns 214,099 shares of the biotechnology company’s stock worth $20,168,000 after acquiring an additional 119,185 shares during the period. Palo Alto Investors LP grew its holdings in shares of BioMarin Pharmaceutical by 1.9% in the first quarter. Palo Alto Investors LP now owns 2,545,482 shares of the biotechnology company’s stock worth $206,362,000 after acquiring an additional 47,676 shares during the period. DnB Asset Management AS bought a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $1,959,000. Jump Trading LLC bought a new stake in shares of BioMarin Pharmaceutical in the first quarter worth $240,000. Finally, Bellevue Group AG grew its holdings in shares of BioMarin Pharmaceutical by 11.7% in the second quarter. Bellevue Group AG now owns 49,519 shares of the biotechnology company’s stock worth $4,665,000 after acquiring an additional 5,169 shares during the period.

Shares of BMRN stock traded up $0.69 during mid-day trading on Friday, hitting $101.01. The company’s stock had a trading volume of 1,411,300 shares, compared to its average volume of 1,322,259. BioMarin Pharmaceutical has a 52-week low of $75.81 and a 52-week high of $106.20. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.83 and a quick ratio of 2.24. The stock has a market capitalization of $18.02 billion, a P/E ratio of -150.76 and a beta of 1.60.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Featured Article: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.